Cidara <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports Q3 net loss of $83.2 million and cash holdings of $476.5 million
Cidara Therapeutics reported cash, cash equivalents, restricted cash, and available-for-sale investments of $476.5 million as of September 30, 2025, up from $196.2 million at the end of 2024. The company reported a net loss of $83.2 million for the third quarter of 2025 and $132.4 million for the first nine months of 2025, compared to net losses of $16.0 million and $117.5 million for the same periods in 2024, respectively. During the period, Cidara advanced its Phase 3 ANCHOR study for CD388, with over 50 percent enrollment reached and target enrollment of 6,000 participants expected by December 2025. The company also received a $45.0 million milestone payment from Janssen following the initiation of Phase 3, a BARDA award to support manufacturing and clinical development, and Breakthrough Therapy designation from the FDA for CD388.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cidara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001610618-25-000094), on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.